Market Tracker

01/30 6:05pm ET

Merck & Co Inc (NYSE:MRK)

60.28
Data as of Jan 30
 -1.81 / -2.92%
Today’s Change
51.92
Today|||52-Week Range
63.62
+6.15%
Year-to-Date
US profitability: the rich list
Jan 30 / FT.com
Young Investors Are Buying the Wrong Stocks
Jan 21 / MotleyFool.com
Roche confident of regaining lead in cancer drugs race
Jan 28 / FT.com
Thanks, Obamacare! Health insurer stocks soar
Jan 21 / CNNMoney.com
Fast Money Halftime Report Final Trade From January 27
Jan 27 / Benzinga
Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog
Jan 20 / Zacks.com
White House Budget To Support Biotech Rally
Jan 27 / Benzinga
Top Trade Ideas For The Week January 20, 2015: Bonus Idea
Jan 18 / StockTwits
Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick
Jan 27 / TheStreet.com
Could This Common Medicine Cabinet Supplement Be the Key to Increased Survival for So...
Jan 18 / MotleyFool.com
Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy
Jan 27 / TheStreet.com
3 Big Pharma Stocks With More Free Cash Flow Than Gilead Sciences Inc.
Jan 18 / MotleyFool.com
Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst Blog
Jan 26 / Zacks.com
J&J receives b,100m EU injection for Ebola vaccine development
Jan 16 / FT.com
This Popular Beverage Could Be Responsible For a 20% Reduction in Melanoma Risk
Jan 26 / MotleyFool.com
Healthcare: Counting the cost of cancer
Jan 15 / FT.com
GSK ships Ebola vaccine to west Africa
Jan 23 / FT.com
Two Ebola vaccines given go-ahead for trials in west Africa
Jan 09 / FT.com
Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog
Jan 22 / Zacks.com
New Ebola vaccine trial starts
Jan 06 / CNNMoney.com